Microbiotix is a biopharmaceutical company developing small molecule drugs targeting infectious diseases and multi-drug resistant pathogens. It provides MBX-400, a nucleoside analog dual DNA polymerase/kinase inhibitor for the treatment of human cytomegalovirus.